glp-1 drugs approved for weight loss GLP1 Drug Use Has Soared Costing Billions GLP-1 Medications Now Recommended First
Description
Greenway, C
Application Analysis The type 2 diabetes mellitus segment had a tremendous growth rate, with a revenue share of 62.3% owing to the well-established role of GLP-1 receptor agonists in improving glycemic control, promoting weight loss, and offering cardiovascular benefits in patients with type 2 diabetes
The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
doi: 10.3390/nu11112566 148 YangFRuanYCYangYJWangKLiangSSHanYBet al
Real-world studies have shown heterogeneous findings
